

**Table. Summary of Treatment-Emergent Adverse Events (TEAEs; N=158)**

<b>TEAE</b>	<b>n (%)</b>
<b>≥ 1 TEAE</b>	<b>119 (75.3)</b>
<b>TEAEs leading to study discontinuation</b>	<b>0</b>
<b>Serious TEAE</b>	<b>45 (28.5)</b>
<b>Most common TEAEs (≥2% of patients)</b>	
Seizure	23 (14.6)
Nasopharyngitis	12 (7.6)
Upper respiratory tract infection	12 (7.6)
Pneumonia	11 (7.0)
Pyrexia	10 (6.3)
Nasal discomfort	9 (5.7)
Influenza	8 (5.1)
Dizziness	7 (4.4)
Headache	7 (4.4)
Somnolence	7 (4.4)
Urinary tract infection	7 (4.4)
Vomiting	7 (4.4)
Sinusitis	6 (3.8)
Constipation	5 (3.2)
Fatigue	5 (3.2)
Status epilepticus	5 (3.2)
Contusion	4 (2.5)
Cough	4 (2.5)
Depression	4 (2.5)
Epistaxis	4 (2.5)
Nasal congestion	4 (2.5)
Nausea	4 (2.5)
Rhinorrhea	4 (2.5)
<b>Treatment-related TEAEs (≥2% patients)</b>	<b>26 (16.5)</b>
Nasal discomfort	9 (5.7)
Headache	4 (2.5)